Frontier IP Group (FIPP) 68.50p £28.85m
Frontier IP, a specialist in commercialising university intellectual property, noted the following announcement from portfolio company Exscientia, a world leader in artificial intelligence ("AI") drug discovery, that it has entered into a drug discovery collaboration with Rallybio.
Rallybio is a US-based drug development company aiming to transform the lives of patients with rare diseases.
Exscientia's other partnerships include collaborations with Celgene, GSK, Roche, Sanofi, GT Apeiron and Evotec. Frontier IP currently holds a 3.25% stake in the Company.